ASRT Assertio Therapeutics Inc.

0.72
-0.01  -1%
Previous Close 0.73
Open 0.71
Price To Book 0.23
Market Cap 57,937,052
Shares 80,681,036
Volume 1,321,989
Short Ratio
Av. Daily Volume 1,647,352
Stock charts supplied by TradingView

NewsSee all news

  1. Ceridian HCM Holding, BJ's Wholesale Club Holdings Set to Join S&P MidCap 400; Oceaneering International, Covetrus to Join S&P SmallCap 600

    NEW YORK, Oct. 30, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 effective prior to the open of trading on Tuesday, November 5: Ceridian

  2. Assertio Therapeutics to Report Third-Quarter 2019 Financial Results After the Close of Markets on Wednesday, November 6, 2019

    LAKE FOREST, Ill., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that it will release third-quarter 2019 financial results on Wednesday, November 6, 2019, after the close

  3. Assertio Therapeutics Provides Regulatory Update on Long-Acting Cosyntropin

    LAKE FOREST, Ill., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT), today announced that its development partner West Therapeutic Development, LLC (West) has received a Complete Response

  4. Assertio Therapeutics Announces Appointment of Dr. David Wheadon to its Board of Directors

    LAKE FOREST, Ill., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) announced today that Dr. David Wheadon has been appointed to the Company's Board of Directors. Dr. Wheadon is a former

  5. Assertio Therapeutics to Present at the Annual Cantor Fitzgerald Global Healthcare Conference

    LAKE FOREST, Ill., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that members of senior management will participate at the Annual Cantor Fitzgerald Global Healthcare

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved January 28, 2011.
GRALISE
Postherpetic neuralgia - shingles
CRL issued May 31, 2013.
SEFELSA
Hot flashes
CRL announced October 21, 2019.
Cosyntropin depot
Adrenocortical insufficiency screening

Latest News

  1. Ceridian HCM Holding, BJ's Wholesale Club Holdings Set to Join S&P MidCap 400; Oceaneering International, Covetrus to Join S&P SmallCap 600

    NEW YORK, Oct. 30, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 effective prior to the open of trading on Tuesday, November 5: Ceridian

  2. Assertio Therapeutics to Report Third-Quarter 2019 Financial Results After the Close of Markets on Wednesday, November 6, 2019

    LAKE FOREST, Ill., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that it will release third-quarter 2019 financial results on Wednesday, November 6, 2019, after the close

  3. Assertio Therapeutics Provides Regulatory Update on Long-Acting Cosyntropin

    LAKE FOREST, Ill., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT), today announced that its development partner West Therapeutic Development, LLC (West) has received a Complete Response

  4. Assertio Therapeutics Announces Appointment of Dr. David Wheadon to its Board of Directors

    LAKE FOREST, Ill., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) announced today that Dr. David Wheadon has been appointed to the Company's Board of Directors. Dr. Wheadon is a former

  5. Assertio Therapeutics to Present at the Annual Cantor Fitzgerald Global Healthcare Conference

    LAKE FOREST, Ill., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that members of senior management will participate at the Annual Cantor Fitzgerald Global Healthcare

  6. Medicenna Strengthens Board of Directors by Appointment of Seasoned Biopharma Executive Ms. Karen Dawes

    Announces Results of Annual Meeting of Shareholders TORONTO and HOUSTON, Sept. 24, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX:MDNA, OTCQB:MDNAF), a clinical stage

  7. Medicenna Strengthens Board of Directors by Appointment of Seasoned Biopharma Executive Ms. Karen Dawes

    Announces Results of Annual Meeting of Shareholders TORONTO and HOUSTON, Sept. 24, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX:MDNA, OTCQB:MDNAF), a clinical